Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSR9 | ISIN: US00032Q1040 | Ticker-Symbol: 3350
Tradegate
27.03.24
17:12 Uhr
2,080 Euro
-0,060
-2,80 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AADI BIOSCIENCE INC Chart 1 Jahr
5-Tage-Chart
AADI BIOSCIENCE INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,1402,22023:00
2,1202,20021:30

Aktuelle News zur AADI BIOSCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.03.Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)26Subgroup experienced efficacy and safety consistent with overall study population Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled...
► Artikel lesen
15.03.Earnings call: Aadi Bioscience sees 60% growth in FYARRO sales3
13.03.Aadi Bioscience, Inc. - 10-K, Annual Report1
13.03.Aadi Bioscience Inc reports results for the quarter ended in December - Earnings Summary1
13.03.Aadi Bioscience GAAP EPS of -$0.60 beats by $0.05, revenue of $6.33M beats by $0.03M1
13.03.Aadi Bioscience, Inc. - 8-K, Current Report1
13.03.Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update329FYARRO® sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023 representing year-over-year growth of 21% and 60%, respectively Registration-directed PRECISION1 trial of nab-sirolimus in solid...
► Artikel lesen
12.03.Aadi Bioscience Earnings Preview2
12.03.Aadi Bioscience Q4 2023 Earnings Preview1
01.03.Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO for the Treatment of Malignant PEComa303After 3 years of follow-up in AMPECT trial, confirmed clinically meaningful overall response rate, including multiple patients with complete responses Demonstrated 40 months median duration of response...
► Artikel lesen
12.02.Aadi Bioscience files for $150M mixed shelf4
12.02.Aadi Bioscience, Inc. - S-8, Securities to be offered to employees in employee benefit plans7
15.12.23Cancer Player Aadi Bioscience Downgraded: Analyst Highlights 'Worse Than Expected' Response Rates8
15.12.23US STOCKS General Electric, BlackRock, Aadi Bioscience14
15.12.23Why Is Aadi Bioscience (AADI) Stock Down 56% Today?7
15.12.23Why Is Anti-Cancer Focused Aadi Bioscience Stock Trading Lower Today?5
15.12.23Aadi Bioscience slides as cancer therapy fails to impress7
15.12.23Aadi Bioscience slumps as cancer therapy misses expectations in study4
14.12.23Aadi Bioscience stock plunges 57% on study data for anti-tumor drug6
14.12.23Aadi Bioscience, Inc. - 8-K, Current Report3
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1